Price: $26.33
· 1 day: +1.78% · 5 days: +5.74% · 1 month: +7.47% · YTD: -5.01%
As of 2026-11-03 21:00 UTC.
52-week range: $20.23 – $38.26 (currently at 34% of the range).
BEAM is in a turning down, momentum firm. $26.38 is the level overhead; $25.81 the first support below.
4 of 6 technical checks lean bullish.
| Trend | Turning down · above 50-day & below 200-day |
|---|---|
| Momentum | RSI 59.99 · neutral · MACD bullish |
| Trend strength | ADX 14.4 · weak or range |
| Location | +2.0% vs 50-day MA |
| 52-week range | -31% from high · +28% from low |
| Volatility | ATR 1.61 · ~6.1%/day |
| Level | Type | Distance |
|---|---|---|
| $26.38 (resistance) | swing zone | 0.19% |
| $27.02 (resistance) | swing zone | 2.62% |
| $28.08 (resistance) | sma 200 | 6.65% |
| $25.81 (support) | sma 50 | -1.97% |
| $25.7 (support) | swing zone | -2.39% |
| $25.0 (support) | round | -5.05% |
| RSI (14) | 59.99 | MACD | 0.3952 |
|---|---|---|---|
| ADX (14) | 14.4 | ATR (14) | 1.61 |
| 50-day average | $25.81 | 200-day average | $28.08 |
Next earnings: 2026-11-03. BEAM earnings date, time and past reactions.
Report of 2026-11-02.
Beam Therapeutics surged on October 29 after early data from its gene‑editing candidate BEAM‑301 suggested a metabolic benefit in a tiny patient cohort. The rally lifted the price to $28.78, but a sharp pull‑back to $26.0 on November 2 erased most of the gain. The balance of evidence now points to a neutral stance for the next two to six weeks, with low conviction because the rally appears limited and the longer‑term trend remains down.
The October 27 press releases from GlobeNewswire and Seeking Alpha highlighted proof‑of‑concept data for BEAM‑301 in glycogen storage disease type Ia. The data showed two patients in the 40 mg cohort achieving a 15‑hour fast without daily starch supplementation, a tangible clinical signal that could eventually underpin a commercial product. The market initially priced this upside, driving the stock up 15.6% to $28.78 on October 29, as reported by NASDAQ.
However, the broader sector context was not supportive. The healthcare‑focused XLV ETF rose only 2.9% over the same five‑day window, while BEAM outperformed the index by 6.4% (stock 9.29% vs sector 2.91%). That outperformance was largely a product of the single news burst rather than a sector‑wide shift. The S&P 500 fell 0.96% over five days, meaning BEAM’s rally was a relative gain against a weakening market.
Analyst sentiment remains extremely optimistic on paper: a consensus “strong buy” from 13 analysts with a mean price target of $49.38, yet the low‑end target sits at $26.0—exactly today’s price—so the valuation spread is wide. The stock trades at a 47.4% discount to the mean target, reflecting the market’s uncertainty about the durability of the clinical news.
The debate among commentators illustrates the split view. Investing.com (October 31) argued the stock was undervalued, citing a fair‑value model of $26.37 and a 64% price jump that exceeded that estimate. By contrast, a Forbes piece on September 25 placed BEAM among gene‑editing stocks that fell after a broader AI‑driven DNA discovery, noting a 6% decline that day and suggesting the sector may be over‑hyped. Both sides rely on the same price data but differ on the interpretation of the underlying growth narrative.
Long‑term, the thesis that BEAM could become a leader in gene‑writing remains intact, but the price is now below its 40‑week average (the long‑term trend is down). The weekly trend is also down, with the 200‑day SMA at $28.11 acting as a resistance level that the stock has not breached since the peak of $28.84 on October 29. The downtrend suggests that the longer‑term structural bias is still negative.
For the next two to six weeks, the balance of evidence leans neutral with low conviction. The assessment notes a rally against the weekly downtrend that is “not yet stretched,” a modest outperformance versus the S&P 500 (+1.7% over 50 days) but a lagging performance versus XLV (‑6.0% over 50 days). The conviction points are only one of four, reflecting the limited breadth of supporting factors. The strongest case against a neutral reading would be a daily close below the 50‑day SMA at $25.85, which would trigger the downside breakout math and shift the bias negative; however, the current price of $26.0 sits just above that level, keeping the downside risk contained for now.
The structure holds the price above $26.38, a swing‑zone level where sellers have historically stepped in on rallies. The weekly trend would be considered ended if a weekly close closes above $27.02, also a swing‑zone resistance. Below those zones, the weekly downtrend would likely resume.
The breakout math is downside‑oriented: a daily close below the 50‑day SMA at $25.85 would signal a breakout. The stop is set at $26.77, derived from $26.38 plus a quarter of the 14‑day ATR ($1.58). Two targets follow the swing‑zone logic: $25.70 (reward‑to‑risk 0.2) and $24.65 (reward‑to‑risk 1.3). The math does not meet a 3‑to‑1 reward‑to‑risk ratio; a price move to roughly $23.5 would be needed to achieve that threshold, which is well below the current swing‑zone support.
A weekly close above $27.02 would invalidate the current neutral stance and suggest the weekly downtrend has ended, opening the path for a higher‑priced rally. The non‑price catalyst that could trigger such a close would be the upcoming earnings release on November 3, where any indication of accelerated clinical timelines or additional data read‑outs could lift sentiment.
Interactive BEAM chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs